Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cytogfr.2020.05.009 http://scihub22266oqcxt.onion/10.1016/j.cytogfr.2020.05.009 32475759!7237916!32475759     free     free     free       Cytokine+Growth+Factor+Rev 2020 ; 53 (ä): 13-24 Nephropedia Template TP {{tp|p=32475759|t=2020. IL-6: Relevance for immunopathology of SARS-CoV-2 |pdf=|usr=}}{{32475759}} gab.com Text IL-6: Relevance for immunopathology of SARS-CoV-2 JO: Cytokine Growth Factor Rev http://www.kidney.de/pget.php?&tw=1&pmid=32475759 #FOAvip COVID-19 mortality is strongly associated with the development of severe pneumonia and acute respiratory distress syndrome with the worst outcome resulting in cytokine release syndrome and multiorgan failure. It is becoming critically important to identify at the early stage of the infection those patients who are prone to develop the most adverse effects. Elevated systemic interleukin-6 levels in patients with COVID-19 are considered as a relevant parameter in predicting most severe course of disease and the need for intensive care. This review discusses the mechanisms by which IL-6 may possibly contribute to disease exacerbation and the potential of therapeutic approaches based on anti-IL-6 biologics. Twit Text FOAVip IL-6: Relevance for immunopathology of SARS-CoV-2 ????Cytokine Growth Factor Rev http://www.kidney.de/pget.php?&tw=1&pmid=32475759 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32475759 #FOAvip English Wikipedia <ref>{{Cite pmid|32475759}}</ref> IL-6: Relevance for immunopathology of SARS-CoV-2 #MMPMID32475759 Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS Cytokine Growth Factor Rev 2020[Jun]; 53 (ä): 13-24 PMID32475759show ga COVID-19 mortality is strongly associated with the development of severe pneumonia and acute respiratory distress syndrome with the worst outcome resulting in cytokine release syndrome and multiorgan failure. It is becoming critically important to identify at the early stage of the infection those patients who are prone to develop the most adverse effects. Elevated systemic interleukin-6 levels in patients with COVID-19 are considered as a relevant parameter in predicting most severe course of disease and the need for intensive care. This review discusses the mechanisms by which IL-6 may possibly contribute to disease exacerbation and the potential of therapeutic approaches based on anti-IL-6 biologics. |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Betacoronavirus/drug effects/immunology/pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/mortality/pathology[MESH] |Cytokine Release Syndrome/*drug therapy/pathology/virology[MESH] |Humans[MESH] |Interleukin-6/*antagonists & inhibitors/blood/immunology[MESH] |Lung Diseases/immunology/pathology/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/mortality/pathology[MESH]IL-6: Relevance for immunopathology of SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing